Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab biomarker study in advanced or metastatic solid tumors
ACTRN12617001059358Phase 2Completed
- Sponsor
- Clinical Network Services
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in Nonhematologic neoplasms, sponsored by Clinical Network Services. Started Aug 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12617001059358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001059358.